Viral vector vaccines

ElsevierVolume 77, August 2022, 102210Current Opinion in ImmunologyHighlights•

The safety of adenoviral vector vaccines is now well-established

Viral vector vaccines are the only licensed vaccines against Ebola virus.

Adenoviral vector vaccines are highly effective in protecting against COVID-19 disease.

Protection is established via induction of both a humoral and cellular response.

Over the past two years, the SARS-CoV-2 pandemic has highlighted the impact that emerging pathogens can have on global health. The development of new and effective vaccine technologies is vital in the fight against such threats. Viral vectors are a relatively new vaccine platform that relies on recombinant viruses to deliver selected immunogens into the host. In response to the SARS-CoV-2 pandemic, the development and subsequent rollout of adenoviral vector vaccines has shown the utility, impact, scalability and efficacy of this platform. Shown to elicit strong cellular and humoral immune responses in diverse populations, these vaccine vectors will be an important approach against infectious diseases in the future.

View Abstract

© 2022 Published by Elsevier Ltd.

留言 (0)

沒有登入
gif